In the intricate world of pharmaceutical manufacturing, the quality of intermediates directly dictates the efficacy and safety of the final drug product. One such crucial compound is 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione, identified by its CAS number 666816-98-4. This chemical entity plays a pivotal role as a key intermediate in the synthesis of Linagliptin, a widely prescribed medication for the management of type 2 diabetes. As a leading pharmaceutical intermediates manufacturer in China, NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing this compound with exceptional purity and reliability.

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the body's own incretin system to improve glycemic control. The complex molecular structure of Linagliptin necessitates the use of precisely synthesized intermediates. Our 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione, presented as an off-white powder, meets the stringent requirement of ≥99.0% purity, making it an ideal starting material for pharmaceutical companies. Understanding the importance of consistent quality, we focus on meticulous production processes to ensure that every batch adheres to the highest standards.

For businesses seeking to buy 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione, partnering with a reputable linagliptin intermediate supplier China is paramount. NINGBO INNO PHARMCHEM CO.,LTD. leverages advanced manufacturing capabilities and rigorous quality control systems to guarantee the integrity of our products. We understand that competitive CAS 666816-98-4 price is crucial for our clients, and we strive to offer cost-effective solutions without compromising on quality. Our expertise in high purity chemical synthesis ensures that your drug development projects are supported by the best possible raw materials.

The physical properties of this intermediate, such as its density and solubility, are well-documented and crucial for efficient handling and reaction kinetics in synthesis. While it is classified as a hazardous material under UN3261 (Class II), necessitating careful handling and adherence to safety protocols, our manufacturing and packaging processes are designed to ensure maximum safety and stability. As a dedicated pharmaceutical intermediates manufacturer, we provide comprehensive documentation and support to our global clientele.

In summary, the role of 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione in the production of Linagliptin cannot be overstated. NINGBO INNO PHARMCHEM CO.,LTD. is committed to being a leading supplier, contributing to the advancement of diabetes treatment through reliable and high-quality pharmaceutical intermediates. We are your trusted partner for sourcing essential chemical building blocks.